Physician profile
Jerome C Hill
NPI 1174605760
$4,654.79
in general payments reported to CMS, 2019-2025
21 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $269 · 2021: $312 · 2022: $481 · 2023: $1,186 · 2024: $922 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,701 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.60 |
| Education | $266.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $934.90 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $703.08 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $541.31 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $473.64 | 2019-2025 | |
| Ucb, INC. | $312.95 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $251.66 | 2022-2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $234.17 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $192.30 | 2020-2025 | |
| Incyte Corporation | $157.36 | 2022-2023 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $153.65 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $123.75 | 2019 | |
| Organon LLC | $110.57 | 2023-2025 | Hadlima, Vtama |
| Pfizer INC. | $93.94 | 2019-2023 | |
| Galderma Laboratories, L.P. | $82.66 | 2019-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $77.93 | 2019-2025 | Taltz, Ebglyss |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.07 | 2023-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $56.70 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.95 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.78 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $15.19 | 2021 | |
| Genentech USA, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.